Heart failure & cardiomyopathies
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial
Primary result · HF event or CV deathResult — go to the resultAdjusted hazard ratio 0.80 95% CI 0.73–0.88Authors' conclusion
Despite KCCQ-TSS being predictive of poor outcomes in this population, women had a 20% lower risk of an HF event or cardiovascular death compared with men. The beneficial effect of omecamtiv mecarbil did not significantly differ by sex.
Study context
- Population
- Symptomatic HF with EF ≤35%, recent HF event and elevated natriuretic peptides, randomised to omecamtiv mecarbil or placebo21.2% women
- Participants
- 8,232 participants
- Comparison
- Women vs men
Primary result
HF event or CV death
Adjusted hazard ratio
0.80
95% CI 0.73–0.88
Womenvs Men
adjusted HR 0.80 (95% CI 0.73–0.88)
As reported in the abstract
Further findings
Omecamtiv mecarbil treatment effect by sex
- Sex did not significantly modify omecamtiv mecarbil's treatment effect
- P for interaction = 0.68
CV death, HF event and all-cause death
- Women had 20% less risk of CV death, HF event and all-cause death
Safety
- Lower rates of serious adverse events in women
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial. JACC Heart Fail. Published 11 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →